Vemurafenib
- Generic Name
- Vemurafenib
- Brand Names
- Zelboraf
- Drug Type
- Small Molecule
- Chemical Formula
- C23H18ClF2N3O3S
- CAS Number
- 918504-65-1
- Unique Ingredient Identifier
- 207SMY3FQT
- Background
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collab...
- Indication
Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E. The V600E mutation, a substitution of glutamic acid for valine, accounts for 54% of the cases of cutaneous melanoma.
...
- Associated Conditions
- Metastatic Melanoma, Refractory Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Refractory Erdheim-Chester disease
- Associated Therapies
- -
Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas
- Conditions
- Interventions
- First Posted Date
- 2012-12-12
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 40
- Registration Number
- NCT01748149
- Locations
- ๐บ๐ธ
Children's Hospital Los Angeles, Los Angeles, California, United States
๐บ๐ธMattel Children's Hospital UCLA, Los Angeles, California, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol
- First Posted Date
- 2012-12-03
- Last Posted Date
- 2021-01-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 215
- Registration Number
- NCT01739764
- Locations
- ๐บ๐ธ
Siouxland Regional Cancer Center d/b/a June E. Nylen Cancer Center, Sioux City, Iowa, United States
๐บ๐ธEvelyn H. Lauder Center, New York, New York, United States
๐บ๐ธUniversity of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT01711632
- Locations
- ๐บ๐ธ
Scripps Clinic, La Jolla, California, United States
๐บ๐ธNorthwestern University, Evanston, Illinois, United States
๐บ๐ธDana Farber Cancer Institute, Boston, Massachusetts, United States
A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 495
- Registration Number
- NCT01689519
- Locations
- ๐ง๐ช
UZ Antwerpen, Edegem, Belgium
๐ฌ๐งVelindre Cancer Centre, Cardiff, United Kingdom
๐ฆ๐บLismore Base Hospital; Cancer Care & Haematology Unit, Lismore, New South Wales, Australia
A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2015-04-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 75
- Registration Number
- NCT01673737
- Locations
- ๐บ๐ธ
Investigational Site Number 840001, Boston, Massachusetts, United States
๐บ๐ธInvestigational Site Number 840002, Houston, Texas, United States
๐บ๐ธInvestigational Site Number 840101, Boston, Massachusetts, United States
A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 498
- Registration Number
- NCT01667419
- Locations
- ๐ท๐บ
Krasnodar City Oncology Center, Krasnodar, Russian Federation
๐ท๐ธMilitary Medical Academy, Belgrade, Serbia
๐ฟ๐ฆMary Potter Oncology Centre, Groenkloof, South Africa
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2024-11-15
- Target Recruit Count
- 17
- Registration Number
- NCT01659151
- Locations
- ๐บ๐ธ
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
- First Posted Date
- 2012-08-06
- Last Posted Date
- 2023-01-19
- Target Recruit Count
- 21
- Registration Number
- NCT01657591
- Locations
- ๐บ๐ธ
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2012-08-03
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT01656642
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธUCLA, Los Angeles, California, United States
๐บ๐ธThe Angeles Clinic and Research Institute - W LA Office, Los Angeles, California, United States
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- First Posted Date
- 2012-07-12
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- University of Louisville
- Target Recruit Count
- 55
- Registration Number
- NCT01638676
- Locations
- ๐บ๐ธ
James Graham Brown Cancer Center-University of Louisville, Louisville, Kentucky, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.